Literature DB >> 16227301

An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction.

Antu K Dey1, Makobetsa Khati, Min Tang, Richard Wyatt, Susan M Lea, William James.   

Abstract

We recently described the isolation and structural characterization of 2'-fluoropyrimidine-substituted RNA aptamers that bind to gp120 of R5 strains of human immunodeficiency virus type 1 and thereby potently neutralize the infectivity of phylogenetically diverse R5 strains. Here we investigate the physical basis of their antiviral action. We show that both N-linked oligosaccharides and the variable loops V1/V2 and V3 are not required for binding of one aptamer, B40, to gp120. Using surface plasmon resonance binding analyses, we show that the aptamer binds to the CCR5-binding site on gp120 in a relatively CD4-independent manner, providing a mechanistic explanation for its neutralizing potency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227301      PMCID: PMC1262572          DOI: 10.1128/JVI.79.21.13806-13810.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120.

Authors:  C Rizzuto; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

2.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

3.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

Review 5.  Chemokines and HIV-1 second receptors: the therapeutic connection.

Authors:  J S Cairns; M P D'Souza
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

6.  Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

Authors:  R E Atchison; J Gosling; F S Monteclaro; C Franci; L Digilio; I F Charo; M A Goldsmith
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

7.  Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.

Authors:  Antu K Dey; Carla Griffiths; Susan M Lea; William James
Journal:  RNA       Date:  2005-06       Impact factor: 4.942

8.  A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.

Authors:  M Farzan; H Choe; L Vaca; K Martin; Y Sun; E Desjardins; N Ruffing; L Wu; R Wyatt; N Gerard; C Gerard; J Sodroski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

Review 10.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

View more
  34 in total

Review 1.  Cell-specific aptamer-mediated targeted drug delivery.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Oligonucleotides       Date:  2010-12-23

Review 2.  Aptamers: multifunctional molecules for biomedical research.

Authors:  Jayeeta Banerjee; Marit Nilsen-Hamilton
Journal:  J Mol Med (Berl)       Date:  2013-09-18       Impact factor: 4.599

3.  An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.

Authors:  Carla Cohen; Mario Forzan; Brian Sproat; Ralph Pantophlet; Ian McGowan; Dennis Burton; William James
Journal:  Virology       Date:  2008-09-17       Impact factor: 3.616

4.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

Review 5.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

6.  UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Authors:  Hazel T Mufhandu; Elin S Gray; Maphuti C Madiga; Nancy Tumba; Kabamba B Alexandre; Thandeka Khoza; Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris; Makobetsa Khati
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 7.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

8.  Aptamer-targeted cell-specific RNA interference.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Silence       Date:  2010-02-01

Review 9.  Aptamers and aptamer targeted delivery.

Authors:  Amy C Yan; Matthew Levy
Journal:  RNA Biol       Date:  2009-07-18       Impact factor: 4.652

10.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.

Authors:  Jiehua Zhou; Piotr Swiderski; Haitang Li; Jane Zhang; C Preston Neff; Ramesh Akkina; John J Rossi
Journal:  Nucleic Acids Res       Date:  2009-03-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.